Abstract
Summary
TNF Alpha Inhibitor are a group of medicines that suppress the body's natural response to tumor necrosis factor (TNF), a protein produced by white blood cells that is involved in early inflammatory events.
LPI (LP Information)' newest research report, the “TNF Alpha Inhibitor Industry Forecast” looks at past sales and reviews total world TNF Alpha Inhibitor sales in 2022, providing a comprehensive analysis by region and market sector of projected TNF Alpha Inhibitor sales for 2023 through 2029. With TNF Alpha Inhibitor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world TNF Alpha Inhibitor industry.
This Insight Report provides a comprehensive analysis of the global TNF Alpha Inhibitor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on TNF Alpha Inhibitor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global TNF Alpha Inhibitor market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for TNF Alpha Inhibitor and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global TNF Alpha Inhibitor.
The global TNF Alpha Inhibitor market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for TNF Alpha Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for TNF Alpha Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for TNF Alpha Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key TNF Alpha Inhibitor players cover AbbVie Inc., Amgen Inc., Johnson and Johnson, UCB SA, Novartis International AG, Pfizer, Merck and co., Janssen Biotech and Ablynx, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of TNF Alpha Inhibitor market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Remicade (Infliximab)
Enbrel (Etanercept)
Humira (Adalimumab)
Cimzia (Certolizumab Pegol)
Simponi (Golimumab)
Segmentation by application
Inflammatory Bowel Disease
Psoriatic Arthritis
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie Inc.
Amgen Inc.
Johnson and Johnson
UCB SA
Novartis International AG
Pfizer
Merck and co.
Janssen Biotech
Ablynx
Momenta
LPI (LP Information)' newest research report, the “TNF Alpha Inhibitor Industry Forecast” looks at past sales and reviews total world TNF Alpha Inhibitor sales in 2022, providing a comprehensive analysis by region and market sector of projected TNF Alpha Inhibitor sales for 2023 through 2029. With TNF Alpha Inhibitor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world TNF Alpha Inhibitor industry.
This Insight Report provides a comprehensive analysis of the global TNF Alpha Inhibitor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on TNF Alpha Inhibitor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global TNF Alpha Inhibitor market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for TNF Alpha Inhibitor and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global TNF Alpha Inhibitor.
The global TNF Alpha Inhibitor market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for TNF Alpha Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for TNF Alpha Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for TNF Alpha Inhibitor is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key TNF Alpha Inhibitor players cover AbbVie Inc., Amgen Inc., Johnson and Johnson, UCB SA, Novartis International AG, Pfizer, Merck and co., Janssen Biotech and Ablynx, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of TNF Alpha Inhibitor market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Remicade (Infliximab)
Enbrel (Etanercept)
Humira (Adalimumab)
Cimzia (Certolizumab Pegol)
Simponi (Golimumab)
Segmentation by application
Inflammatory Bowel Disease
Psoriatic Arthritis
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie Inc.
Amgen Inc.
Johnson and Johnson
UCB SA
Novartis International AG
Pfizer
Merck and co.
Janssen Biotech
Ablynx
Momenta
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global TNF Alpha Inhibitor Market Size 2018-2029
2.1.2 TNF Alpha Inhibitor Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 TNF Alpha Inhibitor Segment by Type
2.2.1 Remicade (Infliximab)
2.2.2 Enbrel (Etanercept)
2.2.3 Humira (Adalimumab)
2.2.4 Cimzia (Certolizumab Pegol)
2.2.5 Simponi (Golimumab)
2.3 TNF Alpha Inhibitor Market Size by Type
2.3.1 TNF Alpha Inhibitor Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global TNF Alpha Inhibitor Market Size Market Share by Type (2018-2023)
2.4 TNF Alpha Inhibitor Segment by Application
2.4.1 Inflammatory Bowel Disease
2.4.2 Psoriatic Arthritis
2.4.3 Ulcerative Colitis
2.4.4 Rheumatoid Arthritis
2.4.5 Ankylosing Spondylitis
2.4.6 Others
2.5 TNF Alpha Inhibitor Market Size by Application
2.5.1 TNF Alpha Inhibitor Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global TNF Alpha Inhibitor Market Size Market Share by Application (2018-2023)
3 TNF Alpha Inhibitor Market Size by Player
3.1 TNF Alpha Inhibitor Market Size Market Share by Players
3.1.1 Global TNF Alpha Inhibitor Revenue by Players (2018-2023)
3.1.2 Global TNF Alpha Inhibitor Revenue Market Share by Players (2018-2023)
3.2 Global TNF Alpha Inhibitor Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 TNF Alpha Inhibitor by Regions
4.1 TNF Alpha Inhibitor Market Size by Regions (2018-2023)
4.2 Americas TNF Alpha Inhibitor Market Size Growth (2018-2023)
4.3 APAC TNF Alpha Inhibitor Market Size Growth (2018-2023)
4.4 Europe TNF Alpha Inhibitor Market Size Growth (2018-2023)
4.5 Middle East & Africa TNF Alpha Inhibitor Market Size Growth (2018-2023)
5 Americas
5.1 Americas TNF Alpha Inhibitor Market Size by Country (2018-2023)
5.2 Americas TNF Alpha Inhibitor Market Size by Type (2018-2023)
5.3 Americas TNF Alpha Inhibitor Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC TNF Alpha Inhibitor Market Size by Region (2018-2023)
6.2 APAC TNF Alpha Inhibitor Market Size by Type (2018-2023)
6.3 APAC TNF Alpha Inhibitor Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe TNF Alpha Inhibitor by Country (2018-2023)
7.2 Europe TNF Alpha Inhibitor Market Size by Type (2018-2023)
7.3 Europe TNF Alpha Inhibitor Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa TNF Alpha Inhibitor by Region (2018-2023)
8.2 Middle East & Africa TNF Alpha Inhibitor Market Size by Type (2018-2023)
8.3 Middle East & Africa TNF Alpha Inhibitor Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global TNF Alpha Inhibitor Market Forecast
10.1 Global TNF Alpha Inhibitor Forecast by Regions (2024-2029)
10.1.1 Global TNF Alpha Inhibitor Forecast by Regions (2024-2029)
10.1.2 Americas TNF Alpha Inhibitor Forecast
10.1.3 APAC TNF Alpha Inhibitor Forecast
10.1.4 Europe TNF Alpha Inhibitor Forecast
10.1.5 Middle East & Africa TNF Alpha Inhibitor Forecast
10.2 Americas TNF Alpha Inhibitor Forecast by Country (2024-2029)
10.2.1 United States TNF Alpha Inhibitor Market Forecast
10.2.2 Canada TNF Alpha Inhibitor Market Forecast
10.2.3 Mexico TNF Alpha Inhibitor Market Forecast
10.2.4 Brazil TNF Alpha Inhibitor Market Forecast
10.3 APAC TNF Alpha Inhibitor Forecast by Region (2024-2029)
10.3.1 China TNF Alpha Inhibitor Market Forecast
10.3.2 Japan TNF Alpha Inhibitor Market Forecast
10.3.3 Korea TNF Alpha Inhibitor Market Forecast
10.3.4 Southeast Asia TNF Alpha Inhibitor Market Forecast
10.3.5 India TNF Alpha Inhibitor Market Forecast
10.3.6 Australia TNF Alpha Inhibitor Market Forecast
10.4 Europe TNF Alpha Inhibitor Forecast by Country (2024-2029)
10.4.1 Germany TNF Alpha Inhibitor Market Forecast
10.4.2 France TNF Alpha Inhibitor Market Forecast
10.4.3 UK TNF Alpha Inhibitor Market Forecast
10.4.4 Italy TNF Alpha Inhibitor Market Forecast
10.4.5 Russia TNF Alpha Inhibitor Market Forecast
10.5 Middle East & Africa TNF Alpha Inhibitor Forecast by Region (2024-2029)
10.5.1 Egypt TNF Alpha Inhibitor Market Forecast
10.5.2 South Africa TNF Alpha Inhibitor Market Forecast
10.5.3 Israel TNF Alpha Inhibitor Market Forecast
10.5.4 Turkey TNF Alpha Inhibitor Market Forecast
10.5.5 GCC Countries TNF Alpha Inhibitor Market Forecast
10.6 Global TNF Alpha Inhibitor Forecast by Type (2024-2029)
10.7 Global TNF Alpha Inhibitor Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Information
11.1.2 AbbVie Inc. TNF Alpha Inhibitor Product Offered
11.1.3 AbbVie Inc. TNF Alpha Inhibitor Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 AbbVie Inc. Main Business Overview
11.1.5 AbbVie Inc. Latest Developments
11.2 Amgen Inc.
11.2.1 Amgen Inc. Company Information
11.2.2 Amgen Inc. TNF Alpha Inhibitor Product Offered
11.2.3 Amgen Inc. TNF Alpha Inhibitor Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Amgen Inc. Main Business Overview
11.2.5 Amgen Inc. Latest Developments
11.3 Johnson and Johnson
11.3.1 Johnson and Johnson Company Information
11.3.2 Johnson and Johnson TNF Alpha Inhibitor Product Offered
11.3.3 Johnson and Johnson TNF Alpha Inhibitor Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Johnson and Johnson Main Business Overview
11.3.5 Johnson and Johnson Latest Developments
11.4 UCB SA
11.4.1 UCB SA Company Information
11.4.2 UCB SA TNF Alpha Inhibitor Product Offered
11.4.3 UCB SA TNF Alpha Inhibitor Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 UCB SA Main Business Overview
11.4.5 UCB SA Latest Developments
11.5 Novartis International AG
11.5.1 Novartis International AG Company Information
11.5.2 Novartis International AG TNF Alpha Inhibitor Product Offered
11.5.3 Novartis International AG TNF Alpha Inhibitor Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Novartis International AG Main Business Overview
11.5.5 Novartis International AG Latest Developments
11.6 Pfizer
11.6.1 Pfizer Company Information
11.6.2 Pfizer TNF Alpha Inhibitor Product Offered
11.6.3 Pfizer TNF Alpha Inhibitor Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Pfizer Main Business Overview
11.6.5 Pfizer Latest Developments
11.7 Merck and co.
11.7.1 Merck and co. Company Information
11.7.2 Merck and co. TNF Alpha Inhibitor Product Offered
11.7.3 Merck and co. TNF Alpha Inhibitor Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Merck and co. Main Business Overview
11.7.5 Merck and co. Latest Developments
11.8 Janssen Biotech
11.8.1 Janssen Biotech Company Information
11.8.2 Janssen Biotech TNF Alpha Inhibitor Product Offered
11.8.3 Janssen Biotech TNF Alpha Inhibitor Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Janssen Biotech Main Business Overview
11.8.5 Janssen Biotech Latest Developments
11.9 Ablynx
11.9.1 Ablynx Company Information
11.9.2 Ablynx TNF Alpha Inhibitor Product Offered
11.9.3 Ablynx TNF Alpha Inhibitor Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Ablynx Main Business Overview
11.9.5 Ablynx Latest Developments
11.10 Momenta
11.10.1 Momenta Company Information
11.10.2 Momenta TNF Alpha Inhibitor Product Offered
11.10.3 Momenta TNF Alpha Inhibitor Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Momenta Main Business Overview
11.10.5 Momenta Latest Developments
12 Research Findings and Conclusion